Baxter expects to reach 100% allocation across several IV product codes by the end of 2023. The company plans to increase production capacity through phased updates in late November, mid-December and ...
However, CEO Joe Almeida stressed that the earliest that new products could start to ship from the plant is late November.
The company, which is a key producer for American healthcare providers, was hit by the hurricane when it tore through western ...
Otsuka Holdings will pay ICU Medical an upfront payment of $200 million. The U.S. IV products market has seen ...
U.S. hospitals are experiencing a shortage of IV fluids, triggered by a disruption at Baxter's North Carolina plant following Hurricane Helene. As hospitals have scrambled to conserve supplies, at ...
Abstract and Introduction Rationale for i.v. Antihypertensive Selection Clinical Pharmacology of i.v. Antihypertensives References There are potential concerns with the use of sodium nitroprusside ...
For patients with bodyweight <50 kg, the dose of intravenous (IV) ferric derisomaltose was 20 mg/kg, irrespective of hemoglobin. If bodyweight was 50 kg to <70 kg, the dose of intravenous ferric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback